EMA Authorised: Inaqovi (cedazuridine;decitabine) — Otsuka Pharmaceutical Netherlands B.V.

View source ↗

Summary

The European Medicines Agency authorised Inaqovi, a fixed-dose oral combination of cedazuridine and decitabine, for adult patients with myeloid leukemias. The m…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myeloid Leukemia

Drugs mentioned

• INAQOVI (cedazuridine; decitabine)

Snippet

Status: Authorised. Therapeutic area: Leukemia, Myeloid. MAH: Otsuka Pharmaceutical Netherlands B.V.. Decision date: 10/03/2025